期刊文献+

Chinese Experts Consensus on Biologic Therapy for Psoriasis

原文传递
导出
摘要 Biologic drugs have been increasingly used in the treatment of psoriasis and are especially favorable for severe,recalcitrant,and special-type cases.Therefore,appropriate,effective,and safe use of biologic drugs has drawn attention from dermatologists.For this purpose,Chinese experts majoring in psoriasis analyzed domestic and international research data,summarized current clinical experiences,investigated features of Chinese patients with psoriasis,and finally formulated the present consensus,which provides detailed guidances to clinicians in terms of the principles and methods of the application of biologics,the efficacy and safety profile,patient screening and monitoring,main adverse events and corresponding solutions,and precautions for special patient populations.
出处 《International Journal of Dermatology and Venereology》 2020年第2期76-85,共10页 国际皮肤性病学杂志(英文)
作者简介 Corresponding author:Dr.Wang Gang,Department of Dermatology,Xijing Hospital,The Fourth Military Medical University,Xi’an,Shaanxi 710032,China.E-mail:xjwgang@fmmu.edu.cn;Dr.Zhang Xue-Jun,Department of Dermatology,Huashan Hospital,Fudan University,Shanghai 200040,China.E-mail:ayzxj@vip.sina.com.
  • 相关文献

参考文献1

二级参考文献21

  • 1Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
  • 2Gottlieb AB. Clinical research helps elucidate the role of tumor necrosis factor-or in the pathogenesis of Tl-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus 2003; 12: 190-194.
  • 3Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
  • 4Oh C J, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor ct (TNF-ct) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829-830.
  • 5Girolomoni G, Pastore S, Albanesi C, Cavani A. Targeting tumor necrosis factor-a as a potential therapy in inflammatory skin diseases. Curr Opin Investig Drugs 2002; 3: 1590-1595.
  • 6Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357: 1842-1847.
  • 7Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48: 829-835.
  • 8Scallon B J, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-ct monoclonal antibody cA2 binds recombinant transmembrane TNF-ct and activates immune effector functions. Cytokine 1995; 7:251-259.
  • 9Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010; 34: 314-321.
  • 10Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部